Alteogen Develops Once-Monthly Obesity Treatment
International Patent Filed for Ultra-Long-Acting Platform
Extending Drug Efficacy by Combining Multiple Active Molecules
Animal Studies Confirm Suppression of Weight Regain After Treatment Discontinuation
Alteogen announced on the 17th that it has completed an international patent application (PCT) for its ultra-long-acting platform technology, the 'long-acting conjugate,' which combines multiple active molecules to extend the duration of drug efficacy.
This technology advances existing platforms that selectively conjugate drugs to specific sites of antibodies. It enables the implementation of multiple active molecules into a single conjugate to prolong a drug's half-life. The company explained that this approach can reduce dosing frequency and extend dosing intervals, making it applicable to the development of long-acting therapeutics.
Alteogen is currently developing 'ALT-M5,' a candidate for obesity treatment that can be administered once a month by applying this platform. Animal studies have confirmed both the possibility of once-monthly dosing with ALT-M5 and its ability to suppress weight regain (rebound) after discontinuation. Detailed results are scheduled to be released at a scientific conference.
The research findings will be presented at 'ObesityWeek 2026,' the annual meeting of The Obesity Society in the United States, which will be held November 14-17 in Washington, D.C. The study covers the effectiveness of a once-monthly injectable incretin fusion protein in suppressing weight regain.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Taeyeon Jeon, CEO of Alteogen, stated, "The technology for which we have filed a patent is a platform applicable to various biopharmaceuticals, enabling the development of long-acting, once-monthly dosing formulations. Based on the results from ALT-M5 animal studies, we plan to develop a differentiated obesity treatment that meets unmet needs by enabling once-monthly administration and suppressing weight regain after discontinuation."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.